{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"IXHL","limit":50},"count":50,"signals":[{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"ch of the following individuals is c/o Incannex Healthcare Inc., Rialto South Tower Level 23, 525 Collins Street Melbourne VIC 3008 Australia. |  | |  Shares Beneficially Owned | | | |  Directors and Named Executive Officers: | |  Number | | |  Percent | | | |  Joel Latham(1) | |  | 1,686,822 | | |  | | * | | |  Troy Valentine(2) | |  | 1,084,284 | | |  | | * | | |  Peter Widdows(3) | |  | 281,897 | | |  | | * | | |  Dr","filed_date":"2025-10-27","accession":"0001213900-25-102654","full_text":"https://origin.rootz.global/static/filing/0001213900-25-102654.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":124,"context":"he state. Failure to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement action that could have a material adverse effect on our business, operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circu","filed_date":"2025-09-29","accession":"0001213900-25-092837","full_text":"https://origin.rootz.global/static/filing/0001213900-25-092837.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":19,"context":"meeting, and information about Incannex Healthcare Inc. that you should consider when you vote your shares are described in the accompanying proxy statement. At the annual meeting, one person will be elected to our board of directors. In addition, we will ask stockholders to (i)&#x00a0;ratify the appointment of Grant Thornton Audit Pty Ltd as our independent registered public accounting firm for our fiscal year ending June&#x00a","filed_date":"2024-11-12","accession":"0001213900-24-096099","full_text":"https://origin.rootz.global/static/filing/0001213900-24-096099.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"connection with a Marketable Security (including any of the above), regardless of whether it has been issued or not. | | | | Facility Agreement Incannex | 10 | | |  |  Term |  |  Definition | | |  |  Material Adverse Effect |  |  means: (a)  as it relates to a person, a material adverse effect: (i)  on the persons condition (financial or otherwise) operations, assets, property or business; or (ii)  on the persons abilit","filed_date":"2024-10-15","accession":"0001213900-24-087764","full_text":"https://origin.rootz.global/static/filing/0001213900-24-087764.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":124,"context":"ch state. Failure to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement action that could have a material adverse effect on our business, operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circu","filed_date":"2024-09-30","accession":"0001213900-24-082937","full_text":"https://origin.rootz.global/static/filing/0001213900-24-082937.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"executive officers and directors as of June 30, 2024. There are no arrangements or understandings between any director or officer and any other person pursuant to which such director or officer was selected as a director or officer. |  Name |  |  Age |  |  Position(s) | | |  |  |  |  |  | | |  Executive Officers |  |  |  |  | | |  Joel Latham |  |  35 |  |  Chief Executive Officer, President and Director | | |  Joseph Swan |  |","filed_date":"2024-09-30","accession":"0001213900-24-082937","full_text":"https://origin.rootz.global/static/filing/0001213900-24-082937.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"Date shall have the meaning ascribed to such term in Section 5.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 4.1(b). Material Permits shall have the meaning ascribed to such term in Section 4.1(n). Maximum Rate shall have the meaning ascribed to such t","filed_date":"2024-09-10","accession":"0001213900-24-077119","full_text":"https://origin.rootz.global/static/filing/0001213900-24-077119.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"any of these risks materialize, we could experience significant delays or an inability to successfully develop and commercialize our drug candidates we or our partners may develop, which would have a material adverse effect on our business, financial condition and results of operations. **Positive results from preclinical studies of our drug candidates are not necessarily predictive of the results of our planned clinica","filed_date":"2024-07-03","accession":"0001213900-24-058785","full_text":"https://origin.rootz.global/static/filing/0001213900-24-058785.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"g. Documentation on the formulation development and cGMP manufacture will support our FDA IND application that we commenced preparations of in August 2023. ** *Monash University* In December 2020, we entered into a partnership agreement with Monash University (Monash) in Australia to conduct a psilocybin-assisted psychotherapy trial to treat GAD. Monash sponsored our initial Phase 2 exploratory clinical trial, ensuring rigorous scie","filed_date":"2024-07-03","accession":"0001213900-24-058785","full_text":"https://origin.rootz.global/static/filing/0001213900-24-058785.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"any of these risks materialize, we could experience significant delays or an inability to successfully develop and commercialize our drug candidates we or our partners may develop, which would have a material adverse effect on our business, financial condition and results of operations. **Positive results from preclinical studies of our drug candidates are not necessarily predictive of the results of our planned clinica","filed_date":"2023-10-31","accession":"0001213900-23-081650","full_text":"https://origin.rootz.global/static/filing/0001213900-23-081650.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"ny of these risks materializes, we could experience significant delays or an inability to successfully develop and commercialize our drug candidates we or our partners may develop, which would have a material adverse effect on our business, financial condition and results of operations. **Positive results from preclinical studies of our drug candidates are not necessarily predictive of the results of our planned clinica","filed_date":"2022-10-28","accession":"0001213900-22-066882","full_text":"https://origin.rootz.global/static/filing/0001213900-22-066882.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":141,"context":"he state. Failure to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement action that could have a material adverse effect on our business, operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circu","filed_date":"2026-09-25","accession":"0001628280-26-063506","full_text":"https://origin.rootz.global/static/filing/0001628280-26-063506.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"o assays. We initiated an Australian Phase 2 trial investigating IHL-675A in rheumatoid arthritis patients; however, in November 2024, we paused patient recruitment due to slower than anticipated enrollment and subsequently terminated the trial. Insufficient data was collected to make any conclusions on safety or efficacy of IHL-675A. We continue to assess the potential development strategies for IHL","filed_date":"2026-09-25","accession":"0001628280-26-063506","full_text":"https://origin.rootz.global/static/filing/0001628280-26-063506.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"ychological support from trained therapists before, during and after each dose session. The psychotherapy comprises three distinct phases: |  | Preparation psychotherapy: conducted following full enrollment and prior to the first dosing session with a key focus on explaining the concept of the trial and principles of the psychotherapy program to the patient, gaining and understanding of the patients","filed_date":"2025-09-29","accession":"0001213900-25-092837","full_text":"https://origin.rootz.global/static/filing/0001213900-25-092837.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"logical support from trained therapists before, during and after each dose session. The psychotherapy comprises three distinct phases: |  |  |  Preparation psychotherapy: conducted following full enrollment and prior to the first dosing session with a key focus on explaining the concept of the trial and principles of the psychotherapy program to the patient, gaining and understanding of the patients","filed_date":"2024-09-30","accession":"0001213900-24-082937","full_text":"https://origin.rootz.global/static/filing/0001213900-24-082937.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":40,"match_count":5,"context":"&#x00a0;&#x00a0;each person known to us to be the beneficial owner of more than 5% of our outstanding common stock; &#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;each of our named executive officers and directors; and &#x2022;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;all of our current executive officers and directors as a group. The beneficial ownership of our common stock presented be","filed_date":"2025-04-28","accession":"0001213900-25-036057","full_text":"https://origin.rootz.global/static/filing/0001213900-25-036057.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":36,"match_count":2,"context":"d Uncertainties** The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry. The Company believes that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, product candidates; performance of thir","filed_date":"2024-05-15","accession":"0001213900-24-043391","full_text":"https://origin.rootz.global/static/filing/0001213900-24-043391.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":36,"match_count":2,"context":"and Uncertainties The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry. The Company believes that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, product candidates; performance of thir","filed_date":"2024-02-14","accession":"0001213900-24-013611","full_text":"https://origin.rootz.global/static/filing/0001213900-24-013611.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":33,"match_count":1,"context":"its through specific mindful, emotion and somatic-focused therapy, meaning-centered support, and facilitating contextual changes that support outcomes. | | ** *Monash University* In December 2020, we entered into a partnership agreement with Monash University (Monash) in Australia to conduct a psilocybin-assisted psychotherapy trial to treat GAD. Monash sponsors our initial Phase 2 exploratory clinical trial, ensuring rigorous scien","filed_date":"2023-10-31","accession":"0001213900-23-081650","full_text":"https://origin.rootz.global/static/filing/0001213900-23-081650.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"been no Material Adverse Effect since the date hereof (v) such Purchaser shall have received a certificate of an officer of the Company, dated as of the First Closing Date, certifying, as to the fulfillment of the conditions set forth in subparagraphs (i), (ii), (iii) and (iv) above (vi) such Purchaser shall have received confirmation satisfactory to it that all approvals of Governmental Authorities","filed_date":"2024-09-10","accession":"0001213900-24-077119","full_text":"https://origin.rootz.global/static/filing/0001213900-24-077119.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":31,"match_count":2,"context":"d Uncertainties** The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry. The Company believes that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, drug candidates; performance of third-p","filed_date":"2026-02-13","accession":"0001213900-26-015867","full_text":"https://origin.rootz.global/static/filing/0001213900-26-015867.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":31,"match_count":2,"context":"d Uncertainties** The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry. The Company believes that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, product candidates; performance of thir","filed_date":"2025-11-14","accession":"0001213900-25-110299","full_text":"https://origin.rootz.global/static/filing/0001213900-25-110299.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":31,"match_count":2,"context":"d Uncertainties** The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry. The Company believes that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, product candidates; performance of thir","filed_date":"2025-05-15","accession":"0001213900-25-043682","full_text":"https://origin.rootz.global/static/filing/0001213900-25-043682.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":31,"match_count":2,"context":"d Uncertainties** The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry. The Company believes that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, product candidates; performance of thir","filed_date":"2025-02-14","accession":"0001213900-25-013783","full_text":"https://origin.rootz.global/static/filing/0001213900-25-013783.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":31,"match_count":2,"context":"d Uncertainties** The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry. The Company believes that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, product candidates; performance of thir","filed_date":"2024-11-14","accession":"0001213900-24-098421","full_text":"https://origin.rootz.global/static/filing/0001213900-24-098421.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"ecurities Act that would require the registration of any such securities under the Securities Act. (xx) No Material Defaults. Neither the Company nor any of its subsidiaries has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, could reasonably be expected to result in a Material Adverse","filed_date":"2025-05-28","accession":"0001213900-25-047988","full_text":"https://origin.rootz.global/static/filing/0001213900-25-047988.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"ecurities Act that would require the registration of any such securities under the Securities Act. (xx) No Material Defaults. Neither the Company nor any of its subsidiaries has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, could reasonably be expected to result in a Material Adverse","filed_date":"2025-04-07","accession":"0001213900-25-029418","full_text":"https://origin.rootz.global/static/filing/0001213900-25-029418.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":24,"match_count":3,"context":"/images/2025-04-04_logo.svg --- EX-99.1 2 ea023706101ex99-1_incannex.htm PRESS RELEASE OF INCANNEX HEALTHCARE INC., DATED APRIL 3, 2025 **Exhibit 99.1** **Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)** Topline Phase 2 clinical data expected in the first half 2025 NEW YORK and MELBOURNE, Austral","filed_date":"2025-04-03","accession":"0001213900-25-028373","full_text":"https://origin.rootz.global/static/filing/0001213900-25-028373.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":23,"match_count":1,"context":"its through specific mindful, emotion and somatic-focused therapy, meaning-centered support, and facilitating contextual changes that support outcomes. | | ** *Monash University* In December 2020, we entered into a partnership agreement with Monash University (Monash) in Australia to conduct a psilocybin-assisted psychotherapy trial to treat GAD. Monash sponsors our initial Phase 2 exploratory clinical trial, ensuring rigorous scien","filed_date":"2022-10-28","accession":"0001213900-22-066882","full_text":"https://origin.rootz.global/static/filing/0001213900-22-066882.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"sents a pivotal period of progress for Incannex as we continue to execute on our IHL-42X development program, said Joel Latham, President and CEO of Incannex. With the rapid completion of Phase 2 enrollment in the Phase 2/3 RePOSA, recent positive and confirmatory PK and safety clinical results, and the addition of expert sleep medicine clinical advisory leadership, we are well-positioned to deliver","filed_date":"2025-05-15","accession":"0001213900-25-043706","full_text":"https://origin.rootz.global/static/filing/0001213900-25-043706.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"a analysis and advance toward our end-of-Phase 2 meeting with the FDA. The third quarter of 2025 represents a pivotal period of progress for the company. With the successful completion of Phase 2 enrollment, encouraging pharmacokinetic and safety data, and expanded clinical advisory expertise, we are well-positioned to advance IHL-42X as a potential first-in-class oral treatment for millions of patie","filed_date":"2025-05-14","accession":"0001213900-25-042962","full_text":"https://origin.rootz.global/static/filing/0001213900-25-042962.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"t step in fostering collaboration as we advance our global Phase 2/3 RePOSA clinical study in OSA. |  | The RePOSA Global Phase 2/3 clinical trial is progressing well, with strong recruitment and enrollment at the U.S. sites. Building on the positive momentum and continued interest in patient recruitment, the trial design includes expansion to both U.K. and U.S. sites for the Phase 3 trial. Additiona","filed_date":"2025-02-14","accession":"0001213900-25-013787","full_text":"https://origin.rootz.global/static/filing/0001213900-25-013787.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"es due to unforeseen circumstances at contract research organizations and vendors along their supply chain; | | |  |  |  increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting a virus, being forced to quarantine, or not wanting to attend hospital visits; | | |  |  |  diversion of healthcare resources away from the conduct of clinical trials, i","filed_date":"2024-07-03","accession":"0001213900-24-058785","full_text":"https://origin.rootz.global/static/filing/0001213900-24-058785.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":16,"match_count":2,"context":"onverted to Great Britain marketing authorizations on January 1, 2021. From January 1, 2021 to December 31, 2023, the MHRA may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required. As of January 1, 20","filed_date":"2024-07-03","accession":"0001213900-24-058785","full_text":"https://origin.rootz.global/static/filing/0001213900-24-058785.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"es due to unforeseen circumstances at contract research organizations and vendors along their supply chain; | | |  |  |  increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting a virus, being forced to quarantine, or not wanting to attend hospital visits; | | |  |  |  diversion of healthcare resources away from the conduct of clinical trials, i","filed_date":"2023-10-31","accession":"0001213900-23-081650","full_text":"https://origin.rootz.global/static/filing/0001213900-23-081650.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":16,"match_count":2,"context":"onverted to Great Britain marketing authorizations on January 1, 2021. From January 1, 2021 to December 31, 2023, the MHRA may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required. As of January 1, 20","filed_date":"2023-10-31","accession":"0001213900-23-081650","full_text":"https://origin.rootz.global/static/filing/0001213900-23-081650.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"es due to unforeseen circumstances at contract research organizations and vendors along their supply chain; | | |  |  |  increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting a virus, being forced to quarantine, or not wanting to attend hospital visits; | | |  |  |  diversion of healthcare resources away from the conduct of clinical trials, i","filed_date":"2022-10-28","accession":"0001213900-22-066882","full_text":"https://origin.rootz.global/static/filing/0001213900-22-066882.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":16,"match_count":2,"context":"which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures. In some other countries, particularly the Member States of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiatio","filed_date":"2026-09-25","accession":"0001628280-26-063506","full_text":"https://origin.rootz.global/static/filing/0001628280-26-063506.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":8,"match_count":1,"context":"e and New York 25 March 2026 **Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced it has entered into a Partnership Agreement with the American Academy of Sleep Medicine (AASM) Foundation. Through this partnership, Incannex has joined the AASM Foundations Corporate Recognition Program and will sponsor a Focused Projects Gra","filed_date":"2026-03-25","accession":"0001213900-26-033842","full_text":"https://origin.rootz.global/static/filing/0001213900-26-033842.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":8,"match_count":1,"context":"rs to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic, cybersecurity and reputational risk. 12 The audit committee reviews information regarding liquidity and operations as well as oversees our management of financial risks. Periodically, the audit committee r","filed_date":"2025-10-27","accession":"0001213900-25-102654","full_text":"https://origin.rootz.global/static/filing/0001213900-25-102654.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"backlog_growth","strength":8,"match_count":1,"context":"al data packages, further validating the strength of our development platform and positioning the Company exceptionally well for its next stage of growth. With an extremely strong cash position and a robust pipeline of combination therapies, we believe Incannex is well-placed to continue executing on its strategy and driving long-term value for shareholders. Incannex remains committed to full compliance with all","filed_date":"2025-10-22","accession":"0001213900-25-100985","full_text":"https://origin.rootz.global/static/filing/0001213900-25-100985.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":8,"match_count":1,"context":"which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures. 57 In some other countries, particularly the Member States of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotia","filed_date":"2025-09-29","accession":"0001213900-25-092837","full_text":"https://origin.rootz.global/static/filing/0001213900-25-092837.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"evelopment efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials and the availability of data or results of these trials, and the potential benefits, safety or of Incannexs drug candidates. Forward-looking statements are statements other than h","filed_date":"2025-07-25","accession":"0001213900-25-067474","full_text":"https://origin.rootz.global/static/filing/0001213900-25-067474.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"evelopment efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials and the availability of data or results of these trials, and the potential benefits, safety or of Incannexs drug candidates. Forward-looking statements are statements other than h","filed_date":"2025-06-24","accession":"0001213900-25-056901","full_text":"https://origin.rootz.global/static/filing/0001213900-25-056901.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"evelopment efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials and the availability of data or results of these trials, and the potential benefits, safety or of Incannexs drug candidates. Forward-looking statements are statements other than h","filed_date":"2025-06-18","accession":"0001213900-25-055407","full_text":"https://origin.rootz.global/static/filing/0001213900-25-055407.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"evelopment efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials and the availability of data or results of these trials, and the potential benefits, safety or of Incannexs drug candidates. Forward-looking statements are statements other than h","filed_date":"2025-06-17","accession":"0001213900-25-054952","full_text":"https://origin.rootz.global/static/filing/0001213900-25-054952.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"evelopment efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials and the availability of data or results of these trials, and the potential benefits, safety or of Incannex's drug candidates. Forward-looking statements are statements other than","filed_date":"2025-06-12","accession":"0001213900-25-053588","full_text":"https://origin.rootz.global/static/filing/0001213900-25-053588.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"evelopment efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials and the availability of data or results of these trials, and the potential benefits, safety or of Incannexs drug candidates. Forward-looking statements are statements other than h","filed_date":"2025-06-03","accession":"0001213900-25-050327","full_text":"https://origin.rootz.global/static/filing/0001213900-25-050327.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"evelopment efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials and the availability of data or results of these trials, and the potential benefits, safety or of Incannexs drug candidates; Incannexs ability to raise sufficient capital from its","filed_date":"2025-05-29","accession":"0001213900-25-048507","full_text":"https://origin.rootz.global/static/filing/0001213900-25-048507.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IXHL","company":"Incannex Healthcare Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":8,"match_count":1,"context":"evelopment efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials and the availability of data or results of these trials, and the potential benefits, safety or of Incannexs drug candidates. Forward-looking statements are statements other than h","filed_date":"2025-05-28","accession":"0001213900-25-048001","full_text":"https://origin.rootz.global/static/filing/0001213900-25-048001.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"8daf50248347d940ad460a4ddaaa04785dcfe00c1fe2c0c4ce0fcfe76af21681","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"ebadc250daf17296a6199df59db2d4b9f4e8dc1a7ff25ce78c0c085ac42974c5","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":12,"hourly_limit":500,"remaining":488,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}